Tagged with association

Austria Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles facing drug innovation under the new reimbursement system, as well as the steps that must be taken to bolster the…

Iceland Jakob Falur Gardarsson, general manager at Frumtök, the Icelandic Association of the Pharmaceutical Industry, highlights access as the main challenge that needs to be met in order to propel Iceland’s healthcare system to the level of other Northern European countries. He also expresses his trust in the willingness of the…

Austria Dr. Andreas Windischbauer, president of the Austrian Association of Full-Line Pharmaceutical Wholesalers (PHAGO) discusses the organization’s role within the Austrian pharma industry, its current challenges, price pressures, competition, and future prospects. Can you give us a brief overview of PHAGO? “We live in a changing world with a lot of…

Indonesia Saanjay Shamdasany, Director of Government Affairs & Public Policy at Baxter and Head of the Pharmaceutical and Life Sciences Committee at American Chamber of Commerce Indonesia, explains the importance of the collaboration between international healthcare companies and the national government to enhance the Indonesian healthcare system. Mr. Sanjaay, could you…

Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…

USA Helen Stimson, president of the Delaware BioScience Association, discusses Delaware’s attractive cost of living, legal system, interconnectivity, as well as the vital role that the life sciences play within the state. Ms. Stimson, after a distinguished career with Agilent Technologies, you became president of the Delaware BioScience Association just a…

Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…

Indonesia Darodjatun Sanusi, Executive Director of GP Farmasi (National Association of Local Companies in Indonesia), explains the opportunities and challenges that his members are facing as well as the future directions that the industry should take to further enhance its capabilities and continue its growth. As Executive Director of GP Farmasi,…

Ukraine Andy Hunder, president, and Maxim Proskurov, policy officer for healthcare issues, at the American Chamber of Commerce (AmCham Ukraine), provide insights into the Chamber’s main actions and strategic priorities as well as an analysis of the ever-changing business ecosystem of Ukraine, more specifically healthcare, and the role of the AmCham…

Colombia Thomas Voigt, executive president of the German Chamber of Commerce in Colombia for seven years, discusses the gradual decentralisation of business in Colombia and the increasingly long-term commitment of German companies to this market. Can you give us a brief history of German Chamber of Commerce in Colombia? “German companies…

Colombia Cristhian Salamanca, executive director of the Colombia-India Chamber of Commerce and Industry discusses the ties between both countries, the important role of the chamber in attracting Indian companies to Colombia, and the ease of doing business for pharmaceutical companies in the country after obtaining INVIMA approval. Could you please provide…

Colombia Executive president of ACEMI (La Asociación Colombiana de Empresas de Medicina Integral), Jaime Arias, discusses fostering the constructive participation of all actors in the Colombian healthcare sector and the challenges that need to be addressed to develop the sustainability of the healthcare system in the long-term. Could you explain ACEMI’s…